BAY 299 can also improve the efficacy of bispecific anti-PD-1/PD-L1 antibodies by stimulating immune cells and encouraging functional transitions, especially in high-grade serous ovarian cancer. The gene discussed is CD274; the disease is ovarian serous adenocarcinoma.